Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 3
1946 1
1947 11
1948 18
1949 14
1950 1
1951 40
1952 65
1953 67
1954 86
1955 70
1956 78
1957 64
1958 54
1959 53
1960 57
1961 46
1962 49
1964 9
1965 94
1966 242
1967 340
1968 397
1969 375
1970 484
1971 514
1972 516
1973 634
1974 578
1975 561
1976 538
1977 588
1978 665
1979 608
1980 643
1981 658
1982 712
1983 702
1984 793
1985 822
1986 852
1987 847
1988 822
1989 900
1990 994
1991 1022
1992 1024
1993 1100
1994 1182
1995 1165
1996 1161
1997 1236
1998 1276
1999 1233
2000 1400
2001 1385
2002 1583
2003 1674
2004 1594
2005 1768
2006 1999
2007 2060
2008 2097
2009 2138
2010 2331
2011 2416
2012 2562
2013 2511
2014 2660
2015 2760
2016 2582
2017 2499
2018 2484
2019 2553
2020 2707
2021 2812
2022 2271
2023 2126
2024 2248
2025 2266
2026 549

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

78,078 results

Results by year

Filters applied: . Clear all
Page 1
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.
Sehn LH, Hübel K, Luminari S, Scholz CW, Salar A, Paneesha S, Wahlin BE, Panayiotidis P, Lee HP, Jiménez-Ubieto A, Sancho JM, Kim TM, Domingo Domenech E, Kumode T, Poh C, Thieblemont C, Deeren D, de Wit E, Arbushites M, Vassallo I, Trneny M; inMIND Study team. Sehn LH, et al. Lancet. 2026 Jan 10;407(10524):133-146. doi: 10.1016/S0140-6736(25)01778-7. Epub 2025 Dec 5. Lancet. 2026. PMID: 41360064 Clinical Trial.
Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma.
Kaulen LD, Karschnia P, Doubrovinskaia S, Abramson JS, Soumerai JD, Martinez-Lage M, Haydu JE, Shankar GM, Patel C, Choi BD, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Wick W, Maus MV, Chen YB, Frigault MJ, Dietrich J. Kaulen LD, et al. J Hematol Oncol. 2026 Jan 14;19(1):2. doi: 10.1186/s13045-025-01761-8. J Hematol Oncol. 2026. PMID: 41530773 Free PMC article.
Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.
Wang S, Nijland M, Strobbe L, Oosterveld M, Boersma R, Koene H, Klerk C, de Jongh E, Koster A, Pruijt H, van der Poel M, van Werkhoven E, Zanders H, Dinmohamed A, Pegtel M, Meek S, Stowell SL, Warinske H, Alizadeh AA, Kurtz DM, Chamuleau MED. Wang S, et al. J Clin Oncol. 2026 Feb 10;44(5):400-409. doi: 10.1200/JCO-25-01712. Epub 2025 Dec 12. J Clin Oncol. 2026. PMID: 41385760 Free PMC article.
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Falchi L, Nijland M, Huang H, Linton KM, Seymour JF, Tao R, Kwiatek M, Costa A, Vassilakopoulos TP, Greil R, Jiménez-Ubieto A, Gangatharan SA, Benjamini O, Thieblemont C, Tucci A, Elinder-Camburn A, Illes A, Novak J, Pavlovsky MA, McDonald A, Yoon DH, Maruyama D, Sunkersett G, Mei JP, Mukherjee N, Zhu F, Alshreef A, Favaro E, Morschhauser F; EPCORE FL-1 Investigators. Falchi L, et al. Lancet. 2026 Jan 10;407(10524):161-173. doi: 10.1016/S0140-6736(25)02360-8. Epub 2025 Dec 7. Lancet. 2026. PMID: 41371238 Free article. Clinical Trial.
Axes of biological variation in diffuse large B cell lymphoma.
Wang B, Wright G, Enssle JC, Yu X, Phelan JD, Yang Y, Shaffer A 3rd, Ruiz AE, Huang DW, Coulibaly Z, Kelly M, Tran B, Pittaluga S, Roschewski M, Wilson WH, Oellerich T, Inghirami G, Staudt LM. Wang B, et al. Cancer Cell. 2026 Mar 9;44(3):567-585.e12. doi: 10.1016/j.ccell.2025.12.015. Epub 2026 Jan 15. Cancer Cell. 2026. PMID: 41544629 Free article.
Large B-cell lymphoma: The LYSA pragmatic guidelines.
Sesques P, Manson G, Dubois S, Gros FX, Brisou G, Sarkozy C, Bernard S, Bourbon E, Fornecker LM, Durot E, Martin L, Chassagne-Clément C, Llamas Gutierrez F, Syrykh C, Delfau-Larue MH, Kanoun S, Vercellino L, Bodet-Milin C, Bahri H, Zhang Yin J, Dony A, Lebras L, Ochmann M, Baron M, Monjanel H, Le Calloch R, Claves F, Kirova Y, Gisselbrecht C, Guidez S, Bossard JB, Di Blasi R, Delette C, Fouillet L, Rhomdani M, Belhadj M, Crochet G, Amorim S, Safa F, Drieu La Rochelle L, Abraham J, Thieblemont C, Jardin F, Noel R, Bailly S, Renaud L, Guillermin Y, Delapierre B, Choquet S, Roulin L, Lamure S, Galicier L, Al Tabaa Y, Soussain C, Guièze R, Houot R, Tessoulin B. Sesques P, et al. Eur J Cancer. 2026 Jan;232:116070. doi: 10.1016/j.ejca.2025.116070. Epub 2025 Dec 3. Eur J Cancer. 2026. PMID: 41352004 Free article.
Risk-Adapted Combined-Modality Therapy in Early-Stage Extranodal Natural Killer-/T-Cell Lymphoma: A Markov Model-Based Cost-Effectiveness Analysis.
Yang J, Zhong QZ, Qian LT, Yang Y, Hou XR, Qiao XY, Wang H, Zhu Y, Cao JZ, Wu JX, Wu T, Zhu SY, Shi M, Zhang HL, Zhang XM, Su H, Song YQ, Zhu J, Zhang YJ, Huang HQ, Wang Y, He X, Zhang LL, Wang SL, Qi SN, Qu BL, Li YX. Yang J, et al. JCO Glob Oncol. 2026 Jan;12:e2400435. doi: 10.1200/GO-24-00435. Epub 2026 Jan 15. JCO Glob Oncol. 2026. PMID: 41538755
78,078 results
You have reached the last available page of results. Please see the User Guide for more information.